国: マルタ
言語: 英語
ソース: Medicines Authority
HUMAN FIBRINOGEN
CSL Behring GmbH Emil-von-Behring-Strasse 76, 35041 Marburg, Germany
B02BB01
HUMAN FIBRINOGEN 1 g
POWDER FOR SOLUTION FOR INJECTION/INFUSION
HUMAN FIBRINOGEN 1 g
POM
ANTIHEMORRHAGICS
Authorised
2017-01-19
Page 1 of 8 PACKAGE LEAFLET: INFORMATION FOR THE USER RIASTAP ® 1 G Powder for solution for injection / infusion Human fibrinogen READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. • Keep this leaflet. You may need to read it again. • If you have any further questions, ask your doctor or pharmacist. • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. • If you get any of side effects talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET: 1. What Riastap is and what it is used for 2. What you need to know before you use Riastap 3. How to use Riastap 4. Possible side effects 5. How to store Riastap 6. Contents of the pack and other information 1. WHAT RIASTAP IS AND WHAT IT IS USED FOR _WHAT IS RIASTAP? _ Riastap contains human fibrinogen which is a protein important for blood clotting (coagulation). Lack of fibrinogen means that the blood does not clot as quickly as it should, which results in an increased tendency of bleeding. The replacement of human fibrinogen with Riastap will correct the coagulation defect. _WHAT IS RIASTAP USED FOR? _ Riastap is used for treatment of bleeding in patients with a congenital lack of fibrinogen (hypo- or afibrinogenaemia) with bleeding tendency. 2. WHAT YOU NEED TO KNOW BEFORE YOU USE RIASTAP The following sections contain information that your doctor should consider before you are given Riastap. DO NOT USE RIASTAP: • if you are allergic to human fibrinogen or any of the other ingredients of this medicine (listed in section 6). PLEASE INFORM YOUR DOCTOR IF YOU ARE ALLERGIC TO ANY MEDICINE OR FOOD. Page 2 of 8 WARNINGS AND PRECAUTIONS: • if you have experienced allergic reactions to Riastap in the past. You should take antihistamines and corticosteroids prophylactically if advised by your doctor. • when allergic 完全なドキュメントを読む
Page 1 of 11 SUMMARY OF PRODUCT CHARACTERISTICS Page 2 of 11 1. NAME OF THE MEDICINAL PRODUCT Riastap 1 g Powder for solution for injection / infusion _ _ 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Riastap is presented as a powder for solution for injection or infusion containing 1 g human fibrinogen per vial. The product reconstituted with 50 ml of water for injections contains approximately 20 mg/ml human fibrinogen. The content of clottable fibrinogen is determined according to the European Pharmacopoeia monograph for human fibrinogen. Excipients recognised to have a known effect: Sodium up to 164 mg (7.1 mmol) per vial. For a full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Powder for solution for injection/infusion. White powder. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Treatment of bleeding in patients with congenital hypo-, or afibrinogenaemia with bleeding tendency. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Treatment should be initiated under the supervision of a physician experienced in the treatment of coagulation disorders. _POSOLOGY_ The dosage and duration of the substitution therapy depend on the severity of the disorder, location and extent of bleeding and the patient’s clinical condition. The (functional) fibrinogen level should be determined in order to calculate individual dosage and the amount and frequency of administration should be determined on an individual patient basis by regular measurement of plasma fibrinogen level and continuous monitoring of the clinical condition of the patient and other replacement therapies used. Page 3 of 11 Normal plasma fibrinogen level is in the range of 1.5 – 4.5 g/l. The critical plasma fibrinogen level below which haemorrhages may occur is approximately 0.5 – 1.0 g/l. In case of major surgical intervention, precise monitoring of replacement therapy by coagulation assays is essential. Initial Dose If the patient’s fibrinogen level is not known, the recommended dose is 70 mg per kg of body weight (BW) administered intraven 完全なドキュメントを読む